Cancer Therapy Advisor1d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
pharmaceuticalcommerce2d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Hosted on MSN2d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
FDA authorizes ImmunityBio to provide rBCG to urologists amid shortages
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
FiercePharma3d
Amid Merck supply squeeze, ImmunityBio and Serum Institute snag FDA blessing for BCG expanded access program
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...